|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
2
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar
|
|
3
|
Zhang ML, Peng P, Wu CX, Gong YM, Zhang
SW, Chen WQ and Bao PP: [Report of breast cancer incidence and
mortality in China registry regions, 2008–2012]. Zhonghua Zhong Liu
Za Zhi. 41:315–320. 2019.(In Chinese).
|
|
4
|
Marth C, Reimer D and Zeimet AG:
Front-line therapy of advanced epithelial ovarian cancer: standard
treatment. Ann Oncol. 28 (Suppl 8):pp. viii36–viii39. 2019,
simplehttps://doi.org/10.1093/annonc/mdx450 View Article : Google Scholar
|
|
5
|
Bieg D, Sypniewski D, Nowak E and Bednarek
I: MiR-424-3p suppresses galectin-3 expression and sensitizes
ovarian cancer cells to cisplatin. Arch Gynecol Obstet.
299:1077–1087. 2019. View Article : Google Scholar
|
|
6
|
Yang B, Sun L and Liang L: MiRNA-802
suppresses proliferation and migration of epithelial ovarian cancer
cells by targeting YWHAZ. J Ovarian Res. 12:1002019. View Article : Google Scholar
|
|
7
|
Ding Y, Fang Q, Li Y and Wang Y:
Amplification of lncRNA PVT1 promotes ovarian cancer proliferation
by binding to miR-140. Mamm Genome. 30:217–225. 2019. View Article : Google Scholar
|
|
8
|
Fan B, Chen LP, Yuan YH, Xiao HN, Lv XS
and Xia ZY: MiR-15a-3p suppresses the growth and metastasis of
ovarian cancer cell by targeting Twist1. Eur Rev Med Pharmacol Sci.
23:1934–1946. 2019.
|
|
9
|
Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and
Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance
of ovarian cancer cells. Neoplasma. 67:93–101. 2020. View Article : Google Scholar
|
|
10
|
Zhang X, Xin G and Sun D: Serum exosomal
miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers
for the diagnosis of Kawasaki disease and the prediction of
therapeutic outcomes of intravenous immunoglobulin therapy. Exp
Ther Med. 16:2420–2432. 2018.
|
|
11
|
Chen CL, Zhang L, Jiao YR, Zhou Y, Ge QF,
Li PC, Sun XJ and Lv Z: miR-134 inhibits osteosarcoma cell invasion
and metastasis through targeting MMP1 and MMP3 in vitro and in
vivo. FEBS Lett. 593:1089–1101. 2019. View Article : Google Scholar
|
|
12
|
Qin Q, Wei F, Zhang J, Wang X and Li B:
miR-134 inhibits non-small cell lung cancer growth by targeting the
epidermal growth factor receptor. J Cell Mol Med. 20:1974–1983.
2016. View Article : Google Scholar
|
|
13
|
Qi A, Han J, Jia F and Liu C: miR-3175 and
miR-134 affect proliferation, invasion and apoptosis of glioma
cells through PI3K/AKT signaling pathway. J BUON. 24:2465–2474.
2019.
|
|
14
|
Ma Z, Li K, Chen P, Pan Q, Li X and Zhao
G: MiR-134, mediated by IRF1, suppresses tumorigenesis and
progression by targeting VEGFA and MYCN in osteosarcoma. Anticancer
Agents Med Chem. 20:1197–1208. 2020. View Article : Google Scholar
|
|
15
|
Greene AL, Snipe JR, Gordenin DA and
Resnick MA: Functional analysis of human FEN1 in Saccharomyces
cerevisiae and its role in genome stability. Hum Mol Genet.
8:2263–2273. 1999. View Article : Google Scholar
|
|
16
|
Gary R, Park MS, Nolan JP, Cornelius HL,
Kozyreva OG, Tran HT, Lobachev KS, Resnick MA and Gordenin DA: A
novel role in DNA metabolism for the binding of Fen1/Rad27 to PCNA
and implications for genetic risk. Mol Cell Biol. 19:5373–5382.
1999. View Article : Google Scholar
|
|
17
|
Gomes XV and Burgers PM: Two modes of FEN1
binding to PCNA regulated by DNA. EMBO J. 19:3811–3821. 2000.
View Article : Google Scholar
|
|
18
|
Nikolova T, Christmann M and Kaina B: FEN1
is overexpressed in testis, lung and brain tumors. Anticancer Res.
29:2453–2459. 2009.
|
|
19
|
Lu X, Liu R, Wang M, Kumar AK, Pan F, He
L, Hu Z and Guo Z: MicroRNA-140 impedes DNA repair by targeting
FEN1 and enhances chemotherapeutic response in breast cancer.
Oncogene. 39:234–247. 2020. View Article : Google Scholar
|
|
20
|
20. Dong S, Xiao Y, Ma X, He W, Kang J,
Peng Z, Wang L and Li Z: miR-193b Increases the chemosensitivity of
osteosarcoma cells by promoting FEN1-mediated autophagy.
OncoTargets Ther. 12:10089–10098. 2019. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Zhang YY, Li P, Zhu MZ, Guo Y and Yang J:
LINC01308 accelerates the malignant progression of ovarian cancer
by binding to miRNA-506. Eur Rev Med Pharmacol Sci. 23:3253–3260.
2019.
|
|
23
|
Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong
FY, Bo T, He J, Hua RX, Hu WD, et al: miR-134: A human cancer
suppressor? Mol Ther Nucleic Acids. 6:140–149. 2017. View Article : Google Scholar
|
|
24
|
Qin Q, Wei F, Zhang J and Li B: miR-134
suppresses the migration and invasion of non-small cell lung cancer
by targeting ITGB1. Oncol Rep. 37:823–830. 2017. View Article : Google Scholar
|
|
25
|
Peng SY, Tu HF, Yang CC, Wu CH, Liu CJ,
Chang KW and Lin SC: miR-134 targets PDCD7 to reduce E-cadherin
expression and enhance oral cancer progression. Int J Cancer.
143:2892–2904. 2018. View Article : Google Scholar
|
|
26
|
Chang C, Liu T, Huang Y, Qin W, Yang H and
Chen J: MicroRNA-134-3p is a novel potential inhibitor of human
ovarian cancer stem cells by targeting RAB27A. Gene. 605:99–107.
2017. View Article : Google Scholar
|
|
27
|
Shuang T, Wang M, Shi C, Zhou Y and Wang
D: Down-regulated expression of miR-134 contributes to paclitaxel
resistance in human ovarian cancer cells. FEBS Lett. 589 (20 Pt
B):3154–3164. 2015. View Article : Google Scholar
|
|
28
|
Prasad R, Dianov GL, Bohr VA and Wilson
SH: FEN1 stimulation of DNA polymerase beta mediates an excision
step in mammalian long patch base excision repair. J Biol Chem.
275:4460–4466. 2000. View Article : Google Scholar
|
|
29
|
Storici F, Henneke G, Ferrari E, Gordenin
DA, Hübscher U and Resnick MA: The flexible loop of human FEN1
endonuclease is required for flap cleavage during DNA replication
and repair. EMBO J. 21:5930–5942. 2002. View Article : Google Scholar
|
|
30
|
Zeng X, Qu X, Zhao C, Xu L, Hou K, Liu Y,
Zhang N, Feng J, Shi S, Zhang L, et al: FEN1 mediates miR-200a
methylation and promotes breast cancer cell growth via MET and EGFR
signaling. FASEB J. 33:10717–10730. 2019. View Article : Google Scholar
|
|
31
|
Abdel-Fatah TM, Russell R, Albarakati N,
Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H,
Abbotts R, et al: Genomic and protein expression analysis reveals
flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian
cancer. Mol Oncol. 8:1326–1338. 2014. View Article : Google Scholar
|
